Drug intelligence / Profile preview

68Ga-MY

Development stage: Unknown
Lead developer: Peking University Cancer Hospital & Institute
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-MY is a novel PET imaging radiopharmaceutical consisting of a nanobody (single-domain antibody) targeting the 5T4 oncofoetal antigen, labeled with the positron-emitting isotope Gallium-68 (68Ga). The 5T4 antigen is a glycoprotein highly expressed on the surface of various solid tumors, including lung and breast cancers, while showing minimal expression in normal adult tissues. Developed by the Peking University Cancer Hospital & Institute, 68Ga-MY is designed to provide high-contrast PET imaging for the detection, staging, and evaluation of 5T4-positive tumors. Its small size as a nanobody allows for rapid blood clearance and efficient tumor penetration, potentially offering superior diagnostic performance compared to standard 18F-FDG PET/CT in specific oncological contexts.

Other names: 68Ga-labeled 5T4-targeted nanobodyGallium-68 MYGallium68 MYGallium 68 MY

Targets

TPBG (Trophoblast glycoprotein)

Beyond the preview

Go deeper on 68Ga-MY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-MY.

Explore the full profile